Cargando…

Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients

Background: The Memorial Sloan–Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiala, Ondrej, Finek, Jindrich, Poprach, Alexandr, Melichar, Bohuslav, Kopecký, Jindrich, Zemanova, Milada, Kopeckova, Katerina, Mlcoch, Tomas, Dolezal, Tomas, Capkova, Lenka, Buchler, Tomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225945/
https://www.ncbi.nlm.nih.gov/pubmed/32230921
http://dx.doi.org/10.3390/cancers12040808
_version_ 1783534171614871552
author Fiala, Ondrej
Finek, Jindrich
Poprach, Alexandr
Melichar, Bohuslav
Kopecký, Jindrich
Zemanova, Milada
Kopeckova, Katerina
Mlcoch, Tomas
Dolezal, Tomas
Capkova, Lenka
Buchler, Tomas
author_facet Fiala, Ondrej
Finek, Jindrich
Poprach, Alexandr
Melichar, Bohuslav
Kopecký, Jindrich
Zemanova, Milada
Kopeckova, Katerina
Mlcoch, Tomas
Dolezal, Tomas
Capkova, Lenka
Buchler, Tomas
author_sort Fiala, Ondrej
collection PubMed
description Background: The Memorial Sloan–Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation of the impact of the MSKCC score on the outcomes in mRCC patients treated with first-line sunitinib, with a focus on the intermediate-risk group. Methods: Clinical data from 2390 mRCC patients were analysed retrospectively. Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analysed according to the MSKCC risk score. Results: ORR, median PFS, and OS for patients with one risk factor were 26.7%, 10.1, and 28.2 months versus 18.7%, 6.2, and 16.2 months, respectively, for those with two risk factors (ORR: p = 0.001, PFS: p < 0.001, OS: p < 0.001). ORR, median PFS, and OS were 33.0%, 17.0, and 44.7 months versus 24.1%, 9.0, and 24.1 months versus 13.4%, 4.5, and 9.5 months in the favourable-, intermediate-, and poor-risk groups, respectively (ORR: p < 0.001, PFS: p < 0.001, OS: p < 0.001). Conclusions: The results of the present retrospective study demonstrate the suitability of the MSKCC model in mRCC patients treated with first-line sunitinib and suggest different outcomes between patients with one or two risk factors.
format Online
Article
Text
id pubmed-7225945
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72259452020-05-18 Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients Fiala, Ondrej Finek, Jindrich Poprach, Alexandr Melichar, Bohuslav Kopecký, Jindrich Zemanova, Milada Kopeckova, Katerina Mlcoch, Tomas Dolezal, Tomas Capkova, Lenka Buchler, Tomas Cancers (Basel) Article Background: The Memorial Sloan–Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation of the impact of the MSKCC score on the outcomes in mRCC patients treated with first-line sunitinib, with a focus on the intermediate-risk group. Methods: Clinical data from 2390 mRCC patients were analysed retrospectively. Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analysed according to the MSKCC risk score. Results: ORR, median PFS, and OS for patients with one risk factor were 26.7%, 10.1, and 28.2 months versus 18.7%, 6.2, and 16.2 months, respectively, for those with two risk factors (ORR: p = 0.001, PFS: p < 0.001, OS: p < 0.001). ORR, median PFS, and OS were 33.0%, 17.0, and 44.7 months versus 24.1%, 9.0, and 24.1 months versus 13.4%, 4.5, and 9.5 months in the favourable-, intermediate-, and poor-risk groups, respectively (ORR: p < 0.001, PFS: p < 0.001, OS: p < 0.001). Conclusions: The results of the present retrospective study demonstrate the suitability of the MSKCC model in mRCC patients treated with first-line sunitinib and suggest different outcomes between patients with one or two risk factors. MDPI 2020-03-27 /pmc/articles/PMC7225945/ /pubmed/32230921 http://dx.doi.org/10.3390/cancers12040808 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fiala, Ondrej
Finek, Jindrich
Poprach, Alexandr
Melichar, Bohuslav
Kopecký, Jindrich
Zemanova, Milada
Kopeckova, Katerina
Mlcoch, Tomas
Dolezal, Tomas
Capkova, Lenka
Buchler, Tomas
Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
title Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
title_full Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
title_fullStr Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
title_full_unstemmed Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
title_short Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
title_sort outcomes according to mskcc risk score with focus on the intermediate-risk group in metastatic renal cell carcinoma patients treated with first-line sunitinib: a retrospective analysis of 2390 patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225945/
https://www.ncbi.nlm.nih.gov/pubmed/32230921
http://dx.doi.org/10.3390/cancers12040808
work_keys_str_mv AT fialaondrej outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients
AT finekjindrich outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients
AT poprachalexandr outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients
AT melicharbohuslav outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients
AT kopeckyjindrich outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients
AT zemanovamilada outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients
AT kopeckovakaterina outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients
AT mlcochtomas outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients
AT dolezaltomas outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients
AT capkovalenka outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients
AT buchlertomas outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients